Off-market insider buying at Devonian Health Group (V:GSD)

Sybil Dahan, a Director, acquired 1,311,553 Subordinate Voting Shares on an indirect ownership basis for registered holder 9294-5039 Québec inc. at a price of $0.352 through a private transaction on November 24th, 2021. This represents a $461,667 investment into the company's shares and an account share holdings change of greater than 100%.

Devonian Health Group is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies, as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a Phase II clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. The Company is also involved in the development of cosmeceutical products.